KRAS and Patent ductus arteriosus: KRAS genetic defects were noted in 111 (88.0%) PDA: KRAS G12D (n = 43, 38.7% of KRAS mutations), G12V (n = 35, 31.5%), G12R (n = 23, 20.7%), G12C (n = 1, 0.9%), Q61 (n = 6, 5%), and KRAS amplification (n = 6, 5%).